Neumora Therapeutics Statistics
Total Valuation
NMRA has a market cap or net worth of $1.47 billion. The enterprise value is $1.05 billion.
| Market Cap | 1.47B |
| Enterprise Value | 1.05B |
Important Dates
The last earnings date was Tuesday, May 7, 2024, before market open.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NMRA has 159.52 million shares outstanding. The number of shares has increased by 439.48% in one year.
| Shares Outstanding | 159.52M |
| Shares Change (YoY) | +439.48% |
| Shares Change (QoQ) | +142.91% |
| Owned by Insiders (%) | 28.77% |
| Owned by Institutions (%) | 48.82% |
| Float | 82.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.45 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.99, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.99 |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.05M |
| Employee Count | 124 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (1Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.91 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 33.93 |
| Average Volume (30 Days) | 608,325 |
Short Selling Information
The latest short interest is 6.58 million, so 4.13% of the outstanding shares have been sold short.
| Short Interest | 6.58M |
| Short Previous Month | 5.87M |
| Short % of Shares Out | 4.13% |
| Short % of Float | 8.01% |
| Short Ratio (days to cover) | 6.19 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Pretax Income | n/a |
| Net Income | -254.02M |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | -$3.63 |
Balance Sheet
The company has $423.93 million in cash and $4.43 million in debt, giving a net cash position of $419.50 million or $2.63 per share.
| Cash & Cash Equivalents | 423.93M |
| Total Debt | 4.43M |
| Net Cash | 419.50M |
| Net Cash Per Share | $2.63 |
| Equity / Book Value | 424.54M |
| Book Value Per Share | 2.66 |
| Working Capital | 418.18M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -439.48% |
| Shareholder Yield | -439.48% |
| Earnings Yield | -17.33% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NMRA is $23.80, which is 158.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.80 |
| Price Target Difference | 158.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -28.39% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |